ANNUAL CAPS AND BASIS OF DETERMINATION. Our Directors estimate that the annual rental receivable by our Group regarding the leasing of the Relevant Property under the Master Tenancy Agreement (Landlord) for each of the three years ending 31 December 2024 will be as follows: FY2022 (RMB million) FY2023 (RMB million) FY2024 (RMB million) In determining the above annual caps, our Directors have considered generally:
ANNUAL CAPS AND BASIS OF DETERMINATION. The historical transaction amount for the procurement of printed packaging materials for pharmaceutical products by the Group from Wing Fat Group for the nine months ended 30 September 2021 amounted to RMB34,280,298. The annual cap for the total procurement amount payable by the Group to the Wing Fat Group for the transactions contemplated under the Procurement Framework Agreement for the year ending 31 December 2022 is RMB80,000,000. The annual cap set out above has been determined after taking into account: (i) the estimated amount of printed packaging materials for pharmaceutical products to be requested by the Group for the year ending 31 December 2022;
ANNUAL CAPS AND BASIS OF DETERMINATION. Our Directors estimate that the annual service fee payable by our Group in respect of the transactions contemplated under the Master Composite Services Agreement for each of the three years ending 31 December 2024 will be as follows: FY2022 (RMB million) FY2023 (RMB million) FY2024 (RMB million) In determining the above annual caps, our Directors have considered generally:
ANNUAL CAPS AND BASIS OF DETERMINATION. By the date of this announcement, the Group had not engaged CSCF for providing any kind of financial services. Therefore, there were no relevant historical transaction figures to be disclosed or made reference to. The Board, having considered (i) the operating cash flow and financial needs of the Group in respect of its future business expansion and the expected growth of the Group in the coming three years; (ii) the Group’s deposit plan made according to its annual revenue; and (iii) the expected amount of interest income from CSCF, resolved that the maximum daily deposit balance (including interests accrued thereon) of the aggregated deposits placed by the Group with CSCF pursuant to the Financial Services Agreement shall not exceed RMB1,200 million (equivalent to approximately HK$1,333 million) for each of the three years ending 31 December 2022, and such have been set as the annual caps for the said deposit services. The Board, having considered (i) the historical cash position of the Group; (ii) the capital turnaround requirement of construction and infrastructure investment business and the liquidity of the business operations of the Group; and (iii) the plan of prorating capital recouping through different methods, resolved that the aggregate transaction amount of bill acceptance and discount services handled by CSCF for the Group shall not exceed RMB1,200 million (equivalent to approximately HK$1,333 million) for each of the three years ending 31 December 2022, and such have been set as the annual caps for the said bill acceptance and discount services.
ANNUAL CAPS AND BASIS OF DETERMINATION. The estimated highest rents for the transactions contemplated under the Property Leasing Framework Agreement for each of the years ending 31 December 2021, 2022 and 2023 are set out below: For the year ending 31 December 2021 2022 2023 (RMB 0’000) Estimated highest rent payable by the Group to Shanghai Pharmaceutical (Group) 10,000 10,000 10,000 For each of the years ending 31 December 2021, 2022 and 2023, the Group will determine the annual caps for leases under the Property Leasing Framework Agreement based on the total value of the right-of-use assets relating to the leases. The proposed annual caps of such right-of-use assets are set out below: For the year ending 31 December 2021 2022 2023 (RMB 0’000) Annual caps 18,000 18,000 18,000 The annual caps set out above have been determined after taking into account: (i) the pricing basis as set out in the Property Leasing Framework Agreement; (ii) the historical amounts of right-of-use assets in respect of the property leasing between the Group and Shanghai Pharmaceutical (Group); (iii) the terms of the existing lease agreements, including their respective expiration dates; and (iv) the Group’s demand in entering into new property leases due to the expansion of business.
ANNUAL CAPS AND BASIS OF DETERMINATION. The proposed annual amounts receivable by the Group from CR Healthcare, its associates and/or hospitals managed by CR Healthcare and/or its associates for the Group’s sales of medical and pharmaceutical products and consumables during the term of the Sales Framework Agreement 2017 are as follows: 0000 XXX HK$ 0000 XXX HK$ Sales of medical and pharmaceutical products and consumables In determining the proposed annual caps for the transactions contemplated under the Sales Framework Agreement 2017, the Company has considered, among others, the following key factors:
ANNUAL CAPS AND BASIS OF DETERMINATION. The proposed annual caps of the procurement of IT Services from CR Digital Group by the Group contemplated under the 2024 Framework Agreement are RMB400,000,000 per annum (exclusive of tax) for the year ending 31 December 2024, the year ending 31 December 2025 and the year ending 31 December 2026, which have been determined with reference to, among others, the following factors: (i) the historical transaction amounts; (ii) the expected scopes and scale of cooperation between the parties; (iii) the expected quality level of infrastructure, services and technical support to be provided by CR Digital Group; and (iv) the Group’s demand on the IT Services for its business development. The continuing connected transactions contemplated under the 2024 Framework Agreement are recurring in nature and will continue in the ordinary and usual course of business of the Group. Set out below are the approximate historical amounts of the continuing connected transactions contemplated under the 2021 Framework Agreement and the 2021 Supplemental Agreement and the annual caps thereunder: Annual cap Approximate historical amounts RMB RMB for the year ended 31 December 2021 120,000,000 28,972,000 for the year ended 31 December 2022 300,000,000 28,384,000 for the year ended 31 December 2023 400,000,000 127,150,000 In compliance with the Listing Rules, the Company has been closely monitoring the continuing connected transactions between the Group and CR Digital Group through various internal control measures. For six months ended 30 June 2024, all applicable percentage ratios set out in Rule 14.07 of the Listing Rules calculated based on the approximate historical amount of continuing connected transactions in respect of the IT Services in the sum of RMB5,643,000 in total are below 0.1%.
ANNUAL CAPS AND BASIS OF DETERMINATION. 2023 CIL Comprehensive Port Logistics Services Framework Agreement Historical Transaction Amount Annual Caps and Basis of Determination – 2023 Hubei Port Comprehensive Port Logistics Services Framework Agreement Historical Transaction Amount
ANNUAL CAPS AND BASIS OF DETERMINATION. Annual caps: In respect of the CDB New Energy Finance Lease Service Framework Agreement, the proposed annual caps for the lease services to be provided by the Company to CDB New Energy for each of the years ending 31 December 2020, 2021 and 2022, respectively, are set out below: (RMB in millions) Basis of Determination:
ANNUAL CAPS AND BASIS OF DETERMINATION. Annual caps: In respect of the Three Gorges Leasing Finance Lease Service Framework Agreement, the proposed annual caps for the lease services to be provided by the Company to Three Gorges Leasing for each of the years ending 31 December 2020, 2021 and 2022, respectively, are set out below: (RMB in millions) Basis of Determination:
